High-dose antioxidants for central serous chorioretinopathy; The randomized placebo-controlled study

Abstract

BackgroundTo determine the efficacy of high-dose antioxidants in the acute stage of central serous chorioretinopathy (CSC).MethodsThis was a randomized placebo-controlled study. The patients with acute CSC (onset within 6 weeks) were randomized to receive either high-dose antioxidant tablets (study group A) or placebo tablets (control group B) for 3 months or until the complete resolution of subretinal fluid. After 3 months, additional treatment with laser or photodynamic therapy (PDT) was considered if any fluorescein leakage persisted. The outcomes measured were the changes in visual acuity (VA) and central macular thickness (CMT), the number of patients with subretinal fluid at each follow-up time, the number of patients with fluorescein leakage at the end of the 3rd month and patients who received additional treatments.ResultsFifty-one of 58 patients (88%) completed the follow-up criteria. The baseline demographic data were comparable in both groups. At the end of the 3rd month, the VA and CMT showed no statistical difference between the groups but the patients in group A has less fluorescein leakage and additional treatments than in group B (p = 0.027 and 0.03).ConclusionThe high-dose antioxidants for acute CSC did not show any benefits in VA and CMT. However, the drugs might decrease the chance for fluorescein leakage and additional treatments at the end of the 3rd month.

Interventions for central serous chorioretinopathy: a network meta-analysis

“…We judged 16 of 24 included studies at unclear risk of bias as they had an appropriate method of random sequence generation, but did not clearly describe how the random sequence was assigned or stored, or they did not clearly describe how the random sequence was generated or stored. We judged one included study at high risk of bias as one of the investigators was involved in the sequence generation and assignment (Ratanasukon 2012). …”

“…Eight studies reported that outcome assessors were masked to treatment group and we judged them at low risk of detection bias (Bae 2011; Browning 1993; Chan 2008; Dang 2013; Ratanasukon 2012; Roisman 2013; Sawa 2014; Zhao 2015). Eight studies did not report any masking and the treatments were different and so we judged them at high risk of detection bias (Boscia 2008; Coskun 2014; Kim 2013; Klatt 2011; Leaver 1979; Lim 2010; Rahbani-Nobar 2011; Semeraro 2012).…”

“…Sawa 2014 excluded 5/39 participants after randomization but did not report which group they were in. Ratanasukon 2012 lost 3/29 participants to follow-up at three months in intervention group and 4/29 in the control group (4/29) but at 12 months, only assessed seven participants in each group. So there was a low risk at three months and high risk for 12 months outcomes.…”

A Multicenter Randomized Controlled Study of Antioxidant Supplementation with Lutein for Chronic Central Serous Chorioretinopathy

“…There was a study reporting that high-dose antioxidants including lutein for acute CSC 164 produced no benefits in either BCVA or central macular thickness at the end of a 3-month administration period. However, this report showed that antioxidant supplementation decreased the chance for fluorescein leakage and additional treatments [37] . Thus, antioxidant supplementation might contribute to reducing the recurrence and incidence rates of CSC, although its impacts on SRD remission were limited.…”

Treatment of Central Serous Chorioretinopathy (Csc) Using Diclofenac through Different Routes of Administration, a Comparative Study

“…Consequently, medications such as antioxidants or antiinflammatories might be effective in decreasing the choroidal leakage especially in the early stages of CSC. Ratanasukon et al [28] administrated either high-dose antioxidant tablet or placebo tablets for 3 months or until complete resolution of sub retinal fluid. An additional treatment with laser or PDT was performed if any fluorescein leakage persisted following 3 months.…”